Pharmaceutical

AstraZeneca files patent for improved production of aav vectors using specific plasmid sequence

Discover how AstraZeneca's new patent revolutionizes AAV vector production with specific polynucleotide sequences, excluding cap genes.

Mar 13, 2024 - 00:00
Discover how AstraZeneca's new patent revolutionizes AAV vector production with specific polynucleotide sequences, excluding cap genes.
Read the original article

Tags:

Previous Article

Zealand Pharma files patent for pharmaceutical composition with GLP-1/GLP-2 dual...

Next Article

Dr. Reddy’s Laboratories files patent for 6-substituted pyridazine compounds for...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Chiesi Farmaceutici gets grant for pharmaceutical formu...

Apr 5, 2024

Adcentrx raises funds to advance ADCs into clinical development

Adcentrx raises funds to advance ADCs into clinical dev...

Apr 26, 2023

GSK’s Nucala for severe eosinophilic asthma gains approval in China

GSK’s Nucala for severe eosinophilic asthma gains appro...

Jan 11, 2024